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PRO-INFLAMMATORY non-pancreatic phospholipase
A2 (sPLA2) is markedly over-expressed in acute
systemic and chronic local inflammatory pro-
cesses. Since in acute phase reaction sPLA2 is
often over-expressed simultaneously with acute
phase proteins (APP), it is important to deter-
mine whether APP interacts with sPLA2. We tested
ten APPs for interaction with sPLA2 using as a
substrate multilamellar Hposomes composed
either of PC:Lyso PC or PE:Lyso PE. Using PC:Lyso
PC substrate, CRP, lactoferrin and SAP were
found to inhibit sPLA2 activity with an ICs0 of 25
g/ml, 7.5 g/ml and 50 g/ml, respectively, cor-
responding to 0.21 M, 0.1 M and 0.21
respectively. Using PE:Lyso PE substrate only SAP
was inhibitory, with an ICs0 of 10 g/ml (0.04
M). Phosphorylcholine abolished the inhibitory
activity of CRP but not of SAP or lactoferrin.
Addition of phosphorylethanolamine or of excess
calcium had no effect on the inhibitory activity of
APP. Limulin, lysozyme, transferrin, 2-micro-
globulin, 2-macroglobulin, human and bovine
albumins had no effect on sPLA2 activity. There-
fore neither the structure of pentraxins, or iron-
binding, bacteriostatic property or amyloidogenic
property preclude whether APP modulates sPLA2
activity. Inhibition of pro-inflammatory sPLA2 by
APP may be one of the protective mechanisms of
the acute phase reaction.
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Introduction
Secretory non-pancreatic phospholipase A2
(sPLA2) belongs to the group of low-molecular-
weight, calcium-dependent, lipolytic enzymes. It
plays an important physiological role in host
defence participating in the destruction of Gram-
negative microorganisms.2’3 sPLA was also found
to exert modulatory activity on the cellular pro-
liferation and tumour formation in the intestinal
tract.4’5 Excessive activity of circulating sPLA2 was
discovered in several systemic inflammatory
response syndromes (SIRS) such as clinical and
experimental sepsi6s,9multiorgan failure and sali-
cylate intoxication,- and in more localized pro-
cesses such as peritonitis and inflammatory
arthritis.’A pathogenetic role of sPLA2 was
implicated by the observation that enzymatic
activity and immunoreactivity of sPLA2 in SIRS
correlated with the severity and outcome of the
disease,6-9 and by the fact that hypotension
induced either by Gram-negative microorgan-
isms
7 or by infusion of sPLA26 could be at-
tenuated by inhibition of the enzyme. Acute
inflammatory processes induced by sPLA2 admin-
istered intracutaneously,
2 into subcutaneous air
14 15 pouches
13 or intraarticularly, could be
blocked by inhibitors of PEA2.12-15
In general terms inhibition of sPLA2 can be
induced by three mechanisms: inhibition of
synthesis, competition for substrate, or direct
inhibition of sPLA2 enzymatic activity. The best
characterized inducers of its synthesis are cyto-
kines, such as IL-1 and TNF.6 IL-6 and oncosta-
tin M induce sPLA2 in cells of hepatic origin such
as Hep G217’18 and normal human liver cells (W.
Pruzanski et al., unpublished). Endotoxin was
also found to be a strong inducer of sPLA2.18
The above observations were consistent with the
postulate that sPLA2 plays an important patho-
genetic role in inflammatory processes and led to
an extensive search for exogenous inhibitors.
However, very little is known about endogenous
modulation of sPLA2. Two endogenous inhibi-
tors, glucocorticoid-inducible lipocortin
9 and
complement fragments
2 have been found, but
neither has evolved into a useful therapeutic
agent.
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During the acute phase reaction the synthesis phosphatidylethanolamine (PE) with or without
and release of sPLA2 occurs simultaneously with LysoPE (2:1) were prepared in chloroform and
that of a large number of acute phase pro- evaporated to dryness. Multilamellar liposomes
teins.1’2 Experimental studies have shown that were made by dispersing the resulting lipid
endotoxin, IL-1, TNF and IL-6 are the main indu- mixture in 100 mM Tris HC1 buffer, pH 8.0,
cers of such release.21’22 Therefore the process followed by heating for 2 min at 41C and vor-
of induction of acute phase proteins by liver cells texing for 2 min before use. Only freshly pre-
seems to be similar to that of sPLA2. Little is pared liposomes were used. Assays were carried
known about the possible interactions of acute out in a total volume of 0.2 ml of 100 mM Tris
phase proteins. We reported recently that CRP, HC1, pH 8.0 containing 2.5 or 10 mM CaCl2, 0.1%
one of the classical acute phase proteins is a bovine serum albumin and 5-30 nmoles of PC
strong inhibitor of sPLA2, binding competitively (or PE) vesicles (containing 2-16 nCi of [4C]
to the phosphorylcholine-containing substrates2 dipalmitoyl PC per assay). The optimal con-
whereas SAA, another acute phase protein, centration was found to be 20 nmoles/assay and
enhances sPLA2 activity.
24 Herein we report that this was used in all experiments. If acute phase
two other acute phase proteins, serum amyloid P proteins were included, they were preincubated
(SAP) and lactoferrin suppress sPLA2 activity, with 20 nmoles of liposomes for 1 h at 41C
These, previously unrecognized, interactions of before the assay. The reaction was then started
acute phase proteins with proinflammatory by addition of 20 l.tl of recombinant human
sPLA2, may add a new aspect to the under- sPLA2 stock solution with final sPLA2 concentra-
standing of the complex role of acute phase tions ranging between 10 and 200 ng/200 l.tl
reaction, assay volume unless otherwise stated. The reac-
tion mixture was then incubated for 30 min at
Materials and Methods 41C. The reaction was stopped by the addition
of 1.32 ml isopropanol/heptane/0.5 M H2SO4
1,2-Dipalmitoyl-phosphatidylcholine (dipalmi- 40:10:1 (v/v/v). The mixture was heated for 1
toyl PC) was obtained from Avanti Polar Lipids min at 60C before addition of 0.66 ml H20 and
(Birmingham, AL). Phosphatidylcholine I-a-dipal- 0.8 ml heptane. The two phases were allowed to
mitoyl [2-palmitoyl-l-4C] (55.5 mCi/mmol) and separate and after centrifugation for 10 min at
oleic acid [1-14C] (40-60 mCi/mmol) were pur- 1 500 rpm, 0.8 ml of the upper phase was added
chased from DuPont NEN Products. t-3-phospha- to 1.0 ml heptane containing 100 mg silica gel.
tidylethanolamine 1-palmitoyl [2-14C linoleoyl] The mixture was spun again for 10 min at 1 500
(50-60 mCi/mmol) was obtained from Amer- rpm and 1.0 ml of the supernatant was used for
sham (Arlington Heights, IL). Recombinant scintillation counting of 42-1abelled free palmitic
human sPLA2 (rh-sPtA2) was a generous gift of acid. All assays were done in triplicate.
Dr Jeffrey Browning, Biogen Corporation (Cam-
bridge, MA). Bio-Rad protein assay reagent was Immunologic assays: Anti-human (mouse IgG2)
purchased from Bio-Rad (Richmond, CA). t-t- CRP/SAP antibody (clone CRP-20) C6552 was
lysophosphatidylcholine palmitoyl, -a-phospha- obtained from Sigma (St Louis, MO). It reacted
tidylethanolamine-]-linoleoyl-y-palmitoyl, -a-lyso- with an epitope located on the 24 kDa subunit
phosphatidylethanolamine palmitoyl, bovine of denatured and reduced CRP and it recognized
serum albumin and silica gel were purchased CRP independently of the Ca
2+ binding site.
from Sigma Chemical Corporation. All reagents This antibody did not recognize the calcium
were analytical grade or better, dependent phosphorylcholine binding site of
Recombinant human lysozyme, bovine serum CRP. It cross-reacted with human SAP, but not
albumin (BSA), human serum albumin (HSA), with CRP from Limulus polyphemus. Working
lactoferrin purified from human milk, transferrin, dilutions were at least 1:4 000 per btg of antigen
[2-microglobulin purified from human urine, in indirect EI.ISA assay. In antibody assays, the
limulin from Limulus polyphemus and ai-macro- antigens were preincubated with appropriately
globulin were obtained from Sigma Chemical diluted antibodies for 60 min at room tempera-
Company (St Louis, MO). CRP purified from rare. Then the liposomal substrate was added
human plasma was obtained from Helix Biotech and the mixture was further incubated for 60
Corporation, Richmond, BC and SAP purified min at 41C. The PEA2 was finally added and the
from human serum, from Calbiochem, San incubation was carried on for an additional 30
Diego, CA. min at 41C.
Each experiment was repeated at least three
Liposome assay: Aliquots of dipalmitoyl PC, [14C] times. The differences between the results and
dipalmitoyl PC, with or without LysoPC (2:1) or controls were assessed by Student’s t-test.
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Results
Ten acute phase proteins were tested for mod-
ulation of sPLA2 activity, using as a substrate mul-
tilamellar liposomes composed either of PC:Lyso
PC or PE:Lyso PE in the ratio of 2:1. Using the
former substrate, lactoferrin (Fig. 1) CRP (Fig. 2)
and SAP (Fig. 3) were inhibitory, with an IC50 of
7.5 l.tg/ml, 25 I.tg/ml and 50 Ig/ml respectively.
These concentrations corresponded to 0.10 I.tM,
0.21 l.tM and 0.21 l.tM respectively (Fig. 4). Using
the latter substrate, only SAP was inhibitory, with
an IC50 of 10 btg/ml (0.04 btM) (Fig. 3). Using
mixed substrate (PE:Lyso PC), no inhibition of
sPLA2 activity by CRP was noted (Table 1).
Addition of phosphorylcholine in concentra-
tions ranging from 0.5 to 10 I.tM abolished inhib-
itory activity of CRP. Fifty per cent attenuation
was achieved by 2.0 btM and complete inhibition
by 10 l,tM of phosphorylcholine.2 Phosphoryl-
choline did not alter inhibitory activity of SAP or
of lactoferrin. Phosphorylethanolamine, 10 l.tM,
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FIG. 1. Inhibition of sPLA2 activity by lactoferrin. Closed squares,
solid line--inhibition of sPLA2 activity using PC:Lyso PC multi-
lamellar liposomes as a substrate. Closed squares, interrupted
line--as above; expression of sPLA2 in nmol/30 min. Closed tri-
angles, solid line--inhibition of sPLA2 activity using PE:Lyso PE
multilamellar liposomes as a substrate. Closed triangles, inter-
rupted line--as above; expresssion of sPLA2 in nmoles/30 min.
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FIG. 2. Inhibition of sPLA2 activity by CRP. Symbols as on Fig. 1.
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FIG. 3. Inhibition of sP2 activity by SAP. Symbols as on Fig. 1.
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FIG. 4. Comparison of inhibitory activity of lactoferrin (squares),
SAP (triangles) and CRP (circles) against sPLA2, expressed in
micromolar concentrations. PC:Lyso PC multilamellar liposomes
used as a substrate.
had no effect on inhibitory activity of SAP, CRP
or lactoferrin.
Anti CRP/SAP monoclonal antibody alone had
no effect on sPLA2 activity. This antibody pre-
incubated with CRP or SAP did not alter their
inhibitory activity in the range of concentrations
used in the assays (CRP or SAP 40 l.tg/ml, sPLA2
100 ng).
To test whether chelation may have an effect
on activity of sPLA2,, various concentrations of
calcium were tested using either PC:Lyso PC orAcute phase proteins and PIA2
Table 1. Impact of substrate on inhibitory activity of CRP
Substrate sPLA2 (nmoles/301)
PE:Lyso PE 0.99
PE:Lyso PE + CRP 1.09
PC:Lyso PC 0.93
PC:Lyso PC + CRP 0.31
PE:Lyso PC 0.93
PE:Lyso PC + CRP 1.35
*sPLA 100 ng, CRP 40 ILtg/ml.
Since the increase in circulatory sPLA2 activity
parallels temporally that of acute phase proteins,
it was of interest to investigate whether there is
an interaction between APPs and sPLA2. Of ten
APPs tested, three were found to inhibit sPLA2
activity. These included CRP, SAP and lactoferrin.
CRP is one of the best studied acute phase pro-
teins, increasing rapidly up to 1000-fold in
APR.34 Both sPLA2 and CRP bind to the phos-
pholipids of perturbed membranes of living
cells2v and to PC:Lyso PC substrate.27’35 It was
found that CRP is a strong inhibitor of sPLA2
PE:Lyso PE as a substrate. Maximum activity of activity, acting most probably as a competitor
sPLA2 was observed at the level of 0.5-1.0 l.tM for the substrate.2 The substrates used in the
Ca
2+ In some experiments with CRP, SAP, or former2 and present study form vesicles of dif-
lactoferrin, Ca
2+ concentrations were increased ferent phospholipid composition. It was found
up to 20 I.tM. Excess of Ca
2+ had no effect on that binding of CRP to such vesicles is pre-
inhibitory activity of these proteins, ferential when they are composed of PC:Lyso PC
Human and bovine serum albumin, transferrin, in the proportion of 2:1. Most probably it is
lysozyme, 2-microglobulin, ai-macroglobulin related to optimally altered surface packing
and limulin had no effect on the activity of sPLA2. density of the substrate. PE:Lyso PE and PE:Lyso
PC substrates were not susceptible to hydrolytic
Discussion activity of sPLA2.
Since CRP belongs to the family of pentrax-
An insult to an organism’s homeostasis caused ins (PEP), two other pentraxins, SAP and
by injury, infection or inflammation, leads to a limulin were also tested. The former was found
swift systemic response called the acute phase to inhibit sPLA2 whereas the latter did not. SAP
reaction (APR) (reviewed in References 21, 25- is a major APP in mice
27 but a minor one in
27). In the case of chronic or recurrent man,6 increasing in APR only three-fold from
inflammation, APR may become quite pro- the physiological level of 30-40 I.tg/ml to no
longed.
25 An integral part of APR is a rapid more than 90 l.tg/ml.27’36 It shares 60% homo-
synthesis and extracellular release of a large logy in amino acid sequence with CRP.2 SAP
number of acute phase proteins (APP), and circulates in the form of two pentameric mole-
simultaneous decrease in some other proteins, cules bound ’face to face’ and, in contrast to
the so called negative APP. Liver is the major CRP, is glycosylated.v The gene for SAP is
source of APP synthesis, but other cells partici- located on the long arm of chromosome 1
pate in the synthesis of APP as well.22’26’28 APR is (1q12-1q23), close to the gene coding for CRP.
orchestrated by a group of inflammatory media- It was suggested that both are products of an
tors, including glucocorticoids, cytokines, ana- ancestral duplication event.8 Whereas CRP
21 25 phylotoxins and growth factors. The group binds mainly to phosphorylcholine,6’9 SAP has
of cytokines which induce APP synthesis high affinity to phosphorylethanolamine.6 In
includes, but is not limited to, IL-1, TNF, IL-6 and our study, SAP inhibited sPLA2 activity when
oncostatin.21’22’26’29’3 either PE:Lyso PE or PC:Lyso PC were used as
The same group of cytokines was also found substrates; however, much lesser concentrations
to induce the synthesis and release of the pro- of SAP were needed to achieve IC50 when
inflammatory enzyme, secretory non-pancreatic PE:Lyso PE was employed. In human serum,
16 18 phospholipase A2 (sPLA2). sPLA2, first dis- SAP binds to C4-binding protein (C4BP) and
covered in experimental peritonitis and in to various types of phospholipid vesicles. These
fluids draining inflammatory sites,2 was found reactions were found to be calcium dependent
to raise rapidly in the circulation in systemic and can be disrupted by phosphorylethanol-
inflammatory response syndromes such as septic amine. In our study phosphorylethanolamine
shock,
7 salicylate poisoning
9 and malaria and did not block the inhibitory activity of SAP.
in the milieu of more localized inflammatory Limulin in Limulus polyphemus is analogous
11 sites such as arthritis. In the former group, cir- to CRP in humans. It shares only 25-30% amino
culating sPLA2 correlated with both complica- acid homology with CRP40’41 and SAP41 and,
tions and the outcome of the disease,
7 whereas similarly to CRP, binds avidly to phosphorylcho-
in the latter it correlated with the disease line.34’42’43 Limulin shares with human CRP two
activity. regions of preserved residues, 52-67, respon-
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Table 2. Acute phase proteins as inhibitors of sPLA2
Group Inhibitors Non-inhibitors
Pentraxins CRP, SAP Limulin
Iron binders Lactoferrin Transferrin
Bacteriostatic Lactoferrin Lysozyme
Amyloidogenic substances SAP SAA*, 2-m
Negative APP HDL* BSA, HSA
Proteinase inhibitors N/D 2-Macroglobulin
ferrin, and enhancers such as SiR24 of sPLA2
activity, emphasizes the complexity of the organ-
ism’s response to injury. Since, in vivo, various
acute phase proteins are over-expressed to very
different orders of magnitude, the end result
regarding their impact on proinflammatory activ-
ity of sPLA2 cannot be predicted.
*Published in Biochem J 1995; 309:461-464.
+N/D: not done.
sible for the binding site to phosphorylcholine
and 139-153 that binds Ca2+.1’44 The fact that,
in contrast to human CRP, limulin does not
inhibit sPLA2 activity, may mean that either the
above two binding sites are not responsible for
inhibition of sPLA2 activity, or that the affinity of
limulin to the substrate is much weaker than
that of CRP. Therefore, pentraxin structure does
not automatically confer anti-sPLA2 activity, since
in contrast to CRP and SAP, limulin was not
inhibitory. Neither am.yloidogenic property of
SAP can be linked to the inhibition of sPLA2,
since SiR24 and [2-microglobulin, both known
participants in amyloidogenesis, did not inhibit
sPLA2 activity (Table 2).
Of three sPLA2 inhibitors, lactoferrin was the
most active. Lactoferrin is one of the iron-carry-
ing proteins, produced mainly by polymorpho-
nuclear cells.45’46 Its synthesis is induced by
TNF45’46 and in sepsis it behaves like a classical
acute phase protein46’47 with the potential to
increase in the circulation ten or more fold from
46 48 its physiological level of 0.2-2.8 mg(.ml.-
Infusions of LPS to healthy volunteers
46 or to
piglets,
48 or of Escherichia coli to piglets47 lead
to a marked increase in circulating lactoferrin. In
turn, lactoferrin interacts with LPS, preventin.
iron-catalysed formation of hydroxyl radicals.
Lactoferrin protects mice against a lethal dose of
E. coli in vivo,
47 acting as bacteriostatic glycopro-
tein and inducing damage to the outer mem-
brane of Gram-negative bacteria.49
It seems, therefore, that lactoferrin acts upon
Gram-negative bacteria similarly to bacterial
permeability increasing protein (BPI).
2 Since
sPLA2 hydrolyses membrane phospholipids of
killed by BPI, the fact that microorganisms
2
lactoferrin inhibits sPLA2 activity may mean that
it acts as a limiting factor in hydrolytic activity
of the latter. The property of iron chelation
by lactoferrin was not related to inhibitory
anti-sPLA2 activity, since transferrin, another iron
chelator did not inhibit sPLA2.
The fact that during the acute phase there is
simultaneous co-induction and over-expression
of both inhibitors such as CRP, SAP and lacto-
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